Cédrik Lafond

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)

Yungan Tao, Anne Aupérin, Xu-Shan Sun et al. · European Journal of Cancer · 2020 · 97 citations · Full text

Medicine, Oncology, Radiation Oncology +11

TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

J. Guigay, Jérôme Fayette, Cédrik Lafond et al. · Journal of Clinical Oncology · 2019 · 82 citations

Medicine, Oncology, Pharmacology +14

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial

Yungan Tao, Xu-Shan Sun, Y. Pointreau et al. · European Journal of Cancer · 2023 · 54 citations · Full text

Medicine, Oncology, Radiation Oncology +14

A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.

Xu Sun, Christian Sire, Yungan Tao et al. · Journal of Clinical Oncology · 2018 · 53 citations

Medicine, Oncology, Radiation Oncology +14